Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 4/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4783677 | 0.83 | SMN1; SMN2 (0.68) | LMNAHPGDHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4785255 | 0.82 | SMN1; SMN2 (0.70) | LMNAHPGDHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4803313 | 0.82 | SMN1; SMN2 (0.70) | LMNAHPGDHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4783720 | 0.82 | HPGD (0.91) | LMNAHPGDHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4785098 | 0.80 | HPGD (0.94) | LMNAHPGDHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4783422 | 0.80 | HPGD (0.94) | LMNAHPGDHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL30133202 | 0.79 | GSK3B (0.48) | LMNAHPGDHTTSMN1; SMN2FYN | |
| SCHEMBL17033289 | 0.78 | HPGD (0.61) | LMNAHPGDHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL19490493 | 0.75 | LMNA (0.57) | LMNAHPGDHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL17037165 | 0.75 | LMNA (0.57) | LMNAHPGDHTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201200-A1 | Methods for Treating Huntington’s Disease | PTC THERAPEUTICS INC (US) | 2023-06-29 | — | — | US | claimed |
| EP-3848035-B1 | 1,4-DISUBSTITUTED PYRIDAZINE COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20230201200-A1 | Methods for Treating Huntington’s Disease | PTC THERAPEUTICS INC (US) | 2023-06-29 | — | — | US | disclosed |
| CN-115605596-A | Compositions and methods for inducible alternative splicing modulation of gene expression | 费城儿童医院（US） | 2023-01-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201200-A1 | Methods for Treating Huntington’s Disease | HTT, HYPK, HDAC6 | LMNA 1244/4885HPGD 317/4885HTT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.